| |
Monotherapy
|
Boost
|
Total
|
p value
|
|---|
|
(n = 155)
|
(n = 63)
|
(n = 218)
|
|---|
|
Age (year)
| | | | |
|
mean ± SD
|
68.1 ± 6.6
|
70.3 ± 6.2
|
68.7 ± 6.5
|
0.023 §
|
|
PSA at diagnosis (ng/mL)
| | | | |
|
mean ± SD
|
7.2 ± 2.4
|
12.5 ± 6.1
|
8.7 ± 4.5
|
< 0.001 §
|
|
10 or less
|
139
|
22
|
161
| |
|
10-20
|
16
|
34
|
50
| |
|
greater than 20
|
0
|
7
|
7
|
< 0.001 ※
|
|
biopsy Gleason score
| | | | |
|
6 or less
|
111
|
22
|
133
| |
|
7
|
44
|
32
|
76
| |
|
8-10
|
0
|
9
|
9
|
< 0.001 ※
|
|
clinical T stage
| | | | |
|
T1c
|
99
|
32
|
131
| |
|
T2a
|
51
|
19
|
70
| |
|
T2b
|
5
|
6
|
11
| |
|
T2c
|
0
|
6
|
6
|
< 0.001 ※
|
|
neoadjuvant/adjuvant ADT
| | | | |
|
none
|
112
|
37
|
149
| |
|
neoadjuvant (+)
|
42
|
18
|
60
| |
|
adjuvant (+)
|
0
|
5
|
5
| |
|
both
|
1
|
3
|
4
|
0.001 ※
|
|
IPSS at baseline
| | | | |
|
mean ± SD
|
8.7 ± 6.9
|
7.2 ± 5.6
|
8.3 ± 6.6
|
0.107 §
|
|
Follow-up period (month)
| | | | |
|
mean ± SD
|
44.2 ± 14.9
|
38.3 ± 16.2
|
42.5 ± 15.5
|
0.011 §
|
- ※ Chi-square test and §t-test.
